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Abstract   44 
Background: Pregnant women with metabolic risk factors are at high risk of complications.  45 
We aimed to assess whether a Mediterranean-style diet reduces adverse pregnancy outcomes 46 
in high-risk women. 47 
Methods and findings: We conducted a multicentre randomised trial in five maternity units 48 
(four in London and one in Birmingham) between 12th September 2014 and 29th February 49 
2016. We randomised inner-city pregnant women with metabolic risk factors (obesity, 50 
chronic hypertension or hypertriglyceridaemia) to a Mediterranean-style diet with high intake 51 
of nuts, extra virgin olive oil, fruits, vegetables, non-refined grains and legumes; moderate-52 
high consumption of fish, low-moderate intake of poultry and dairy products; low intake of 53 
red and processed meat; and avoidance of sugary drinks, fast food, and food rich in animal fat 54 
to usual care. Participants received individualised dietary advice at 18, 20 and 28 weeks’ 55 
gestation. The primary endpoints were composite maternal (gestational diabetes or pre-56 
eclampsia) and composite offspring (stillbirth, small for gestational age or admission to 57 
neonatal care unit) outcomes prioritised by a Delphi survey. We used an intention-to-treat 58 
analysis, with multivariable models and identified the stratification variables and prognostic 59 
factors a priori. 60 
We screened 7950 and randomised 1252 women. Baseline data were available for 593 61 
women in the intervention (93∙3% follow-up, 553/593) and 612 in the control (95∙6 % 62 
follow-up, 585/612) groups. Over a quarter of randomised women were primigravida 63 
(330/1205, 27%), 60% (729/1205) were of Black or Asian ethnicity, and 69% (836/1205) 64 
were obese. Women in the intervention arm consumed more nuts (70∙1% vs. 22∙9%; adjusted 65 
odds ratio [aOR] 6∙8, 95% confidence interval [CI] 4∙3-10∙6, p=<0.001) and extra virgin olive 66 
oil (93∙2% vs. 49∙0%; aOR 32∙2, 95%CI 16∙0-64∙6, p=<0.001) than controls and increased 67 
their intake of fish (p<0∙001), white meat (p<0∙001) and pulses (p=0∙05), and reduced red 68 
meat (p<0∙001), butter, margarine and cream intake (p<0∙001). There was no significant 69 
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reduction in the composite maternal (22∙8% vs. 28∙6%; aOR 0∙76, 95%CI 0∙56-1∙03, p=0.08) 70 
or composite offspring (17∙3% vs. 20∙9%; aOR 0∙79, 95%CI 0∙58-1∙08, p=0.14) outcomes. 71 
There was an apparent reduction in the odds of gestational diabetes by 35% (aOR 0∙65, 72 
95%CI 0∙47-0∙91, p=0.01), but not in other individual components of the composite 73 
outcomes. Mothers gained less gestational weight (mean 6∙8 vs. 8∙3 Kg; adjusted difference -74 
1∙2 Kg, 95%CI -2∙2 to -0∙2, p=0.03) with intervention vs. control. There was no difference in 75 
any of the other maternal and offspring complications between both groups. When we pooled 76 
ESTEEM findings with similar trials using random effects meta-analysis and observed a 77 
significant reduction in gestational diabetes (OR 0.67, 95%CI 0.53-0.84, I²=0%) with no 78 
heterogeneity (two trials, 2397 women). The study’s limitations include the use of participant 79 
reported tools for adherence to the intervention instead of  objective biomarkers. 80 
Conclusions: A simple, individualised, Mediterranean-style diet in pregnancy did not reduce 81 
the overall risk of adverse maternal and offspring complications, but has the potential to 82 
reduce gestational weight gain and the risk of gestational diabetes. 83 
 84 
Trial registration number: NCT02218931 85 
  86 
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Why was this study done?  87 
 A Mediterranean-style diet reduced the risk of type 2 diabetes and cardiovascular 88 
complications in randomised trials involving general population with risk factors. 89 
 To-date, no trial has evaluated the effects of Mediterranean style diet in pregnancy on 90 
maternal and offspring outcomes.  91 
What did the researchers do and find?  92 
 In the ESTEEM study, 1252 pregnant women with metabolic risk factors from five 93 
inner city UK hospitals were randomly allocated to follow a Mediterranean-style diet 94 
(supplemented with mixed nuts and extra virgin olive oil) or routine antenatal care, 95 
and the overall maternal (gestational diabetes or pre-eclampsia), and offspring 96 
outcomes (small-for-gestational age, stillbirth, or admission to the neonatal care unit) 97 
were assessed.  98 
 Pregnant women allocated to the Mediterranean-style diet increased their intake of 99 
key components of this diet and gained on average 1.25 Kg less weight than those 100 
who had routine care.  101 
  There were no statistically significant reductions in overall maternal, and offspring 102 
complications in pregnant women who followed a Mediterranean diet than usual care. 103 
Of the individual outcomes, the risk of gestational diabetes apparently decreased by 104 
35% with the intervention.  105 
 A meta-analysis of ESTEEM study results with a similar trial showed a 33% 106 
reduction in gestational diabetes, but no effect on other outcomes. 107 
What do these findings mean?  108 
 It is feasible to deliver a Mediterranean-style diet to inner-city pregnant women and 109 
increase their uptake of relevant dietary components.  110 
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 Mediterranean-style diet in pregnancy did not improve the overall maternal and 111 
offspring outcomes, but has the potential to prevent gestational diabetes. 112 
 Future studies should assess the effect of in utero exposure to Mediterranean-style 113 
diet, particularly to nuts and olive oil, on childhood obesity, allergy and asthma. 114 
 115 
  116 
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Introduction 117 
One in four mothers enter pregnancy with pre-existing obesity, chronic hypertension or 118 
hyperlipidaemia. [1,2] In addition to complications in pregnancy, these mothers and their 119 
babies are at long-term risk of diabetes and cardiovascular complications. [3] A 120 
Mediterranean-style diet, rich in mono and polyunsaturated fatty acids, reduces the incidence 121 
of cardiovascular diseases in the non-pregnant population. [4–6] In pregnancy, such a diet has 122 
the potential to improve maternal and offspring outcomes by preventing gestational diabetes, 123 
pre-eclampsia, and fetal growth restriction. [7–9]  124 
 125 
In the general population, individuals at high risk of cardiovascular diseases are advised to 126 
follow specific dietary patterns such as DASH (Dietary Approaches to Stop Hypertension). 127 
[10] Despite the publication of numerous randomised trials on diet and lifestyle interventions 128 
in pregnancy, [11] no clear dietary recommendations have emerged to improve pregnancy 129 
outcomes for women with metabolic risk factors. This can be attributed to the variations in 130 
the interventions and the reporting of outcomes, and lack of robust evidence on effectiveness 131 
of the diet. [12] To implement complex dietary interventions in practice, we require clear 132 
definitions of dietary components accompanied by simple guidance to improve adherence to 133 
the diet. [13–15] It is particularly challenging to evaluate such interventions in multi-ethnic 134 
pregnant populations comprising of high-risk women from varied ethnic and socioeconomic 135 
backgrounds. 136 
 137 
We undertook a multicenter pragmatic randomised trial (Effect of Simple, Targeted Diet in 138 
Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes - ESTEEM) to 139 
evaluate in pregnant women with metabolic risk factors, the effects of a Mediterranean-style 140 
diet (supplemented with mixed nuts and extra virgin olive oil) with individualised dietary 141 
advice on maternal and offspring outcomes, compared to routine antenatal care.  142 
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Methods  143 
Trial oversight 144 
The ESTEEM trial was approved by the NHS Research Ethics Committee (UK IRAS Ref 145 
No. 14/EE/1048). The Trial Steering Committee (TSC) provided independent supervision on 146 
all aspects of the trial conduct according to established principles, and approved all protocol 147 
modifications ( S1 Text). [16] An independent Data Monitoring Committee (DMC) 148 
overviewed the trials data management and analysis independently. The California Walnut 149 
Commission and Blue Diamond Growers donated the walnuts, hazelnuts and almonds 150 
without any influence on the study design, conduct, analysis, interpretation or reporting. 151 
Extra virgin olive oil was purchased from industrial suppliers by the trial sponsor and was 152 
provided to the participants in the intervention group for free. The last author assumes 153 
responsibility for the completeness and accuracy of the data and analyses, and for the fidelity 154 
of the trial to the protocol.  155 
 156 
Study design  157 
A randomised controlled trial that recruited women from five inner-city maternity units in the 158 
UK (four in London, one in Birmingham) between 12th September 2014 and 29th February 159 
2016. The trial was prospectively registered with clinicaltrials.gov (NCT02218931), and the 160 
protocol was previously published. [17]  161 
 162 
Participants 163 
Pregnant women were recruited if they were at least 16 years of age, less than 18 weeks’ 164 
gestation with a singleton pregnancy, able to consume nuts and olive oil, and proficient in 165 
written and spoken English. We excluded participants with a history of pre-existing diabetes, 166 
gestational diabetes, chronic renal disease, autoimmune disease, or if they were taking lipid-167 
altering drugs such as statins at the time of booking. After recruitment, we randomised 168 
 8 
women with metabolic risk factors such as obesity (body mass index BMI ≥30 Kg/m2), raised 169 
serum triglycerides (≥1∙7 mmol/L) or chronic hypertension (≥140 mm Hg systolic or ≥90 mm 170 
Hg diastolic blood pressure) to the intervention or control arms. We employed the cut-off 171 
values used to define metabolic risk the general population as the tests were done in early 172 
pregnancy, reflective of the preconception risk status. [18]  173 
 174 
Randomisation  175 
Pregnant women received information about the trial alongside the invitation letter for their 176 
first antenatal booking appointment ( S2 Text). After obtaining consent from eligible women, 177 
we collected baseline information on blood pressure, body mass index, and lipid profile 178 
(triglycerides, low density, high density and very low-density cholesterol) at their booking 179 
visit. Women with at least one of the pre-specified metabolic risk factors  were randomised to 180 
the two arms of the trial in a 1:1 ratio via a password-protected online data management 181 
system. We used minimisation (with a random element to ensure allocation concealment) to 182 
balance the groups for maternal body mass index, parity, and ethnicity.  183 
 184 
Intervention 185 
The ESTEEM intervention was based on a Mediterranean-style diet. The key components of 186 
this diet included high intake of nuts and extra virgin olive oil, fruit and vegetables, non-187 
refined grains and legumes, moderate to high consumption of fish, low to moderate intake of 188 
poultry and dairy products such as yoghurt and cheese, low consumption of red meat and 189 
processed meat, and avoidance of sugary drinks, fast food, and food rich in animal fat. [19] 190 
To promote their intake in pregnancy, we provided participants in the intervention arm with 191 
mixed nuts (30g/day of walnuts, hazelnuts, and almonds) and extra virgin olive oil (0∙5 192 
litre/week) as the main sources of cooking fat. ( S3 Text)  193 
 194 
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The trial dietitian and trained researchers delivered the intervention over three face-to-face 195 
sessions, which included a personalised 1-1 session at 18 weeks’ gestation, and two further 196 
group sessions at 20 and 28 weeks using pre-piloted presentations ( S3 Text). [17] In the first 197 
visit, we used the 24-hour food recall technique to identify any changes that were needed in 198 
the participants’ diet to follow a Mediterranean-style pattern. We made the intervention 199 
culturally sensitive by providing cooking advice through a bespoke recipe book ( S4 Text). 200 
We incorporated elements of the Mediterranean diet into the local cuisine by co-designing the 201 
recipes with community teams (food-academy.co.uk). Where possible, we involved women’s 202 
partners to participate in these sessions. In between the face-to-face sessions, we followed up 203 
the women twice with phone calls at 24 and 32 weeks’ gestation to reinforce the dietary goals 204 
and to assess their general health. We used the number of sessions attended (at 18, 20 and 28 205 
weeks’ gestation) as a marker of adherence.  206 
 207 
We undertook an internal pilot phase to determine the dietary intake of pregnant women 208 
using a validated Food Frequency Questionnaire (FFQ) for Mediterranean diet, and a 209 
modified short questionnaire (ESTEEM Q) that was previously validated for adherence to the 210 
Mediterranean diet in a non-pregnant population. [20] Details of the methods used to validate 211 
the FFQ against the 24-hour dietary recall, and against the ESTEEM Q have been published 212 
elsewhere. [17] Subsequently, we used the ESTEEM Q to assess the intake of dietary 213 
components at 20, 24, 28, 32 and 36 weeks ( S5 Text). [21]  214 
 215 
Participants allocated to the control group received dietary advice as per UK national 216 
recommendations for antenatal care and weight management in pregnancy. [22–24] In 217 
addition to folic acid and vitamin D supplementation, [24] mothers in both groups who were 218 
considered to be at high risk of pre-eclampsia received low dose aspirin (75mg). [23] Both 219 
groups completed questionnaires at 36 weeks’ gestation or at delivery to assess their level of 220 
 10 
physical activity (International Physical Activity Questionnaires IPAQ), gastrointestinal 221 
symptoms, and quality of life including the health thermometer (EQ-5D) (S5 Text). [25]  222 
 223 
Outcome measures 224 
The primary endpoints were a composite maternal outcome combining gestational diabetes or 225 
pre-eclampsia, and a composite offspring outcome combining stillbirth, small for gestational 226 
age fetus, or admission to the neonatal care unit. [17] The individual components of the 227 
composite were identified by a Delphi survey and were rated to be critically important in the 228 
care of pregnant women. [26] Gestational diabetes was defined as either a fasting venous 229 
glucose value of 5∙1 mmol/L or more, or 2-hour values of 8∙5 mmol/L or more following a 230 
75g oral glucose tolerance test (OGTT) as per the modified International Association of 231 
Diabetes and Pregnancy Study Group (IADPSG) criteria. [27] All participants were screened 232 
for gestational diabetes with OGTT as per national guidelines. [28] Pre-eclampsia included 233 
the following: new onset pre-eclampsia defined as onset of hypertension (systolic blood 234 
pressure (BP) ≥ 140 mm Hg or diastolic BP ≥ 90 mmHg, in at least two readings, taken 4-6 235 
hours apart) and new onset proteinuria (spot urine Protein Creatinine Ratio PCR > 236 
30mg/mmol or 24 hour urine protein >300mg or 2+ or more on urine dipstick) after 20 weeks 237 
gestation; and superimposed pre-eclampsia in women with chronic hypertension or chronic 238 
proteinuria ( S6 Text). [23] Small-for-gestational age fetus included babies with birth weight 239 
less than 10th centile on the customised charts that were adjusted for gestation at delivery, 240 
maternal height, weight, parity, and ethnicity. [29]  241 
 242 
The initial primary endpoint was pre-eclampsia. Following the planned internal pilot, the 243 
independent trial steering committee (TSC) recommended the primary endpoint be extended 244 
to include composite maternal outcome, and composite offspring outcome. The Committee 245 
considered both GDM and pre-eclampsia to be major burdens facing women with metabolic 246 
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risk factors, and that a large trial on Mediterranean diet in pregnancy should evaluate these 247 
maternal and the relevant offspring outcomes ranked as critically important to clinical care in 248 
a Delphi survey of researchers. [26] This decision was made independent of the trial 249 
investigators, before completion of data collection and development of the statistical analysis 250 
plan. The change of outcomes was approved by the Research Ethics Committee and was 251 
incorporated in the published protocol. The funders and Sponsor of the study had no 252 
involvement in the revision of end point. 253 
 Our secondary maternal outcomes included gestational diabetes, pre-eclampsia, gestational 254 
weight gain, maternal admission to high dependency or intensive care unit, antepartum 255 
haemorrhage, mode of delivery, preterm delivery and maternal anaemia. Our secondary 256 
offspring outcomes included stillbirths, neonatal deaths, small for gestational age fetus (<10th 257 
centile), admission to the neonatal care unit, birth weight, and hypoxic ischaemic 258 
encephalopathy. The maternal intake of food groups, and levels of triglycerides, high-density 259 
lipoproteins (HDL), the ratio of triglycerides to HDL, and non-high-density lipoprotein 260 
cholesterol (non-HDL) were compared between the two groups.  A dedicated research staff 261 
recorded outcomes from clinical notes and from hospital electronic records following 262 
delivery.  263 
 264 
Statistical analysis 265 
We estimated the composite maternal and composite offspring outcomes to be observed in 266 
24% of women with metabolic risk factors, [30] and expected the intervention to reduce their 267 
occurrence by 30%. [4] We calculated that we needed to analyse data from 982 women to 268 
ensure an 80% power to detect this change at the 5% significance level. To allow for a loss of 269 
20% at follow-up, we planned to randomise 1230 women.  270 
 271 
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The primary analysis was conducted on an intention-to-treat (ITT) basis. Baseline 272 
demographics and clinical characteristics were summarised as percentages for categorical 273 
variables, mean (standard deviation) for normally distributed continuous variables, and 274 
median (interquartile range) for non-normally distributed variables. Participants who were 275 
enrolled in error were excluded post-randomisation. Women who experienced miscarriages 276 
and terminations of pregnancy after randomisation were not included in any analysis of the 277 
offspring outcomes. We reported the effect of the intervention on composite maternal and 278 
fetal outcomes as adjusted odds ratio (aOR) with 95% confidence interval (CI) using a 279 
multivariable logistic regression model. In addition to the minimisation factors, we adjusted 280 
the primary analysis for other factors determined a priori (maternal age, history of gestational 281 
diabetes in a previous pregnancy, stillbirth in a previous pregnancy, family history of 282 
hypertensive disorder or diabetes, and the center of recruitment). [21,28,22] 283 
 284 
We repeated the ITT analysis for the primary composite outcomes in subgroups specified a 285 
priori for women with and without obesity, chronic hypertension and raised triglycerides, and 286 
tested for any interactions. The individual components of the primary outcome, and other 287 
secondary outcomes were analysed using multivariable logistic regression for binary 288 
outcomes, and linear regression for continuous outcomes, with a normalizing transformation 289 
where necessary. Where a continuous outcome was also assessed at baseline, we adjusted for 290 
this as an additional covariate. We only included participants with non-missing outcome in 291 
the primary analysis. This approach is unbiased if the data were ‘missing at random’ i.e. 292 
missingness for the outcome is related to the observed covariates. We investigated the 293 
sensitivity of our conclusions to this assumption, when more than 5% of data for the primary 294 
outcome were missing, by imputing missing outcomes under alternative assumptions, and by 295 
re-estimating the treatment effect.  296 
 297 
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For validation of the FFQ against the 24-hour dietary recall and the ESTEEM Q, we specified 298 
a priori that the agreement using ICC (Intraclass Correlation Coefficient) was good for 299 
nutrient values if the score was above 0∙5, acceptable if between 0∙49-0∙2 and poor if below 300 
0∙2. [32] For Kappa statistics, we considered the agreement to be good for κ > 0∙6, acceptable 301 
for κ 0∙6-0∙2, and poor for κ < 0∙2. [32] Quartile cross-classification for agreement was 302 
considered to be good if ≥ 50% were in the same quartile and ≤ 10% were in opposite 303 
quartile. The agreement was judged as poor if <50% were in the same quartile and >10% 304 
were in the opposite quartile. Values in between these ranges were judged to denote moderate 305 
agreement. [32]  306 
 307 
The study statisticians and the research team were blinded to the analyses and interpretation 308 
of results. An independent statistician provided unblinded summaries and reports using 309 
computer code to the Data Monitoring Committee. All analyses for the trial were conducted 310 
using STATA version 12 or higher (StataCorp, College Station, TX, 2012).  311 
 312 
We inferred the findings of the ESTEEM trial in the context of available evidence by 313 
systematically searching the literature (MEDLINE and EMBASE from inception till January 314 
2019) for similar trials on Mediterranean diet in pregnancy. We extracted the data and pooled 315 
the results using random effects meta-analysis, and reported the effects as OR with 95% CI, 316 
and heterogeneity using I2 estimates. [33] 317 
 318 
 319 
Patient and Public Involvement 320 
We sought input from pregnant women at the trial design stage by conducting a survey of 321 
their views on the feasibility and acceptability of the planned intervention. The Trial Steering 322 
 14 
Committee had a lay representative from Action on Pre-eclampsia (APEC) Charity ( S1 323 
Text).  324 
 325 
Results 326 
We screened 7950 women, recruited 3421, and randomised 1252 women with metabolic risk 327 
factors to the intervention (n=627) or to the control group (n=625). Baseline data were 328 
available for 99% (1237/1252) of the randomised participants; 93% (553/593) in the 329 
intervention and 96% (585/612) in the control groups were followed-up and included in the 330 
analysis. Fig 1 depicts the enrolment, randomisation and follow up of participants in the 331 
ESTEEM trial.     332 
 333 
Fig 1: Enrolment, randomisation and follow up of participants in the ESTEEM trial    334 
  335 
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A third of the randomised women were primigravida (330/1205, 27%), 60% were Black or 336 
Asian (729/1205), 69% (836/1205) were obese, 47% (515/1090) had raised triglycerides at 337 
booking, and 5% (58/1129) entered pregnancy with chronic hypertension (Table 1).  338 
 339 
Table (1): Baseline characteristics of participants in the ESTEEM trial on Mediterranean-340 
style diet in pregnancy  341 
 342 
Maternal characteristics (N intervention; control) Intervention 
groupMean 
(SD) orn (%) 
Control 
groupMean 
(SD) orn (%) 
Maternal age (584; 610)   
Age years (mean SD)Age > 40 years 31.4 (5.2)23 
(3.9%) 
30.9 (5.2)19 
(3.1%) 
Gravidity (593; 612) 
  
Primigravida Multigravida  162 (27.3%)431 
(72.7%) 
168 (27.5%)444 
(72.5%) 
Ethnicity (593; 612) 
  
White Asian BlackOther 217 (36.6%)257 
(43.3%)97 
(16.4%)22 
(3.7%) 
217 (35.5%)270 
(44.1%)105 
(17.2%)20 
(3.3%) 
Body Mass Index (Kg/m2) (593; 612) 
  
Normal (18.5-24.9)Overweight (25.0-29.9)Obese (30.0-39.9) 84 (14.2%)99 
(16.7%)410 
(69.1%) 
84 (13.7%)102 
(16.7%)426 
(69.6%) 
Medical history    
Chronic hypertension (554; 575)Previous history of pre-
eclampsia (575; 600)Previous history of gestational diabetes 
(563; 585)Previous stillbirth or neonatal death (571; 
598)Previous admission to ITU/HDU (530; 557)Family history 
of hypertension/pre-eclampsia (537; 536)Family history of 
diabetes (541; 555) 
27 (4.9%)21 
(3.7%)15 
(2.7%)8 
(1.4%)5 
(0.9%)274 
(51.0%)276 
(51.0%) 
31 (5.4%)29 
(4.8%)22 
(3.8%)14 
(2.3%)10 
(1.8%)276 
(51.5%)303 
(54.6%) 
Serum lipids  
  
Triglycerides mmol/L (532; 558) (mean SD)HDL mmol/L (531; 
557) (mean SD)Ratio of triglycerides to cholesterol (527; 
553)Non-HDL mmol/L (529; 554) (mean SD) 
1.6 (0.7)1.7 
(0.5)0.3 (0.2)3.2 
(0.8) 
1.7 (0.8)1.6 
(0.4)0.3 (0.2)3.3 
(1.6) 
Diet   
ESTEEM Q score (337; 210) (mean SD) 5.0 (1.9) 5.0 (1.9) 
Physical activity    
MET/week (406; 241) (mean SD) 2579.5 (3335.9) 2591.7 (3306.9) 
Health 
Health Thermometer (400; 222) (mean SD) 67.4 (18.7) 71.8 (18.7) 
ITU: intensive treatment unit; HDU: high dependency unit; HDL: high-density lipoprotein; 343 
LDL: low-density lipoprotein. MET: Metabolic Equivalent of Task minutes per week.  344 
 345 
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 346 
Three-quarters (410/553, 74%) of women in the intervention group attended at least one of 347 
the planned intervention sessions. Women were able to receive their nuts and olive oil even 348 
when they missed a session. Mothers allocated to the intervention vs. control group 349 
consumed significantly more nuts (70∙1% vs. 22∙9%, aOR 6∙8, 95% CI 4∙3-10∙6, p=<0.001), 350 
and extra virgin olive oil (93∙2% vs. 49∙0%, aOR 32∙2, 95% CI 16∙0-64∙6, p=<0.001); 351 
increased their intake of key components of the Mediterranean diet such as fish (p<0∙001), 352 
white meat (p<0∙001) and pulses (p=0∙05); and consumed less red meat (p<0∙001), and butter, 353 
margarine and cream (p<0∙001). There were no differences between the groups in their intake 354 
of other food groups or their physical activity (MET) (MD -0∙2, 95% CI -0∙1 to 0∙51, p=0.19). 355 
(Table 2)  356 
 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
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Table (2): Changes in the reported dietary intake, physical activity and health gastrointestinal 371 
symptoms in pregnant women in the ESTEEM trial  372 
   373 
 Maternal diet, symptoms and physical 
activity N (intervention; control) 
Intervention Control  Crude OR or MD^ 
(95% CI) 
Crude  
 p value 
Adjusted OR or 
MD^^ (95% CI) 
Adjusted    
p value 
Dietary intake        
Olive oil as main fat source* (280; 298) 261 (93.2%) 146 (49.0%) 14.30 (8.52, 24.01) <0.001 32.19 (16.03, 64.62) <0.001 
≥4 tbsp. of olive oil/day* (273; 296) 63 (23.1%) 28 (9.5%) 2.87 (1.78, 4.64) <0.001 2.81 (1.55, 5.09) <0.001 
≥3 nut servings/week* (274; 292) 192 (70.1%) 67 (22.9%) 7.86 (5.40, 11.45) <0.001 6.75 (4.28, 10.62) <0.001 
≥3 fish or shellfish servings/week* (276; 297) 101 (36.6%) 67 (22.6%) 1.98 (1.37, 2.86) <0.001 2.57 (1.57, 4.21) <0.001 
Preferential consumption of chicken or turkey 
instead of veal, pork, hamburger or sausage* 
(254; 279) 
221 (87.0%) 224 (80.3%) 1.64 (1.03, 2.63) 0.038 2.34 (1.26, 4.35) 0.007 
≤1 red meat, processed meat or red meat 
products servings/day* (241; 278) 
206 (85.5%) 156 (56.1%) 4.60 (3.00, 7.07) <0.001 3.42 (1.99, 5.86) <0.001 
≤1 butter, margarine, or cream servings/day* 
(268; 291) 
164 (61.2%) 115 (39.5%) 2.41 (1.72, 3.39) <0.001 2.41 (1.55, 3.75) <0.001 
≤1 sugary drinks/day* (269; 295) 149 (55.4%) 121 (41.0%) 1.79 (1.28, 2.49) <0.001 1.40 (0.92, 2.15) 0.12 
≥3 pulse servings/week* (275; 296) 103 (37.5%) 86 (29.1%) 1.46 (1.03, 2.08) 0.033 1.56 (1.00, 2.44) 0.048 
≥3 fruit units/day* (276; 296) 142 (51.4%) 156 (52.7%) 0.95 (0.68, 1.32) 0.76 1.10 (0.72, 1.68) 0.66 
≤3 times consumption of commercial sweets 
or pastries/ week* (276; 292) 
165 (59.8%) 151 (51.7%) 1.39 (1.00, 1.94) 0.053 1.42 (0.92, 2.19) 0.11 
≥2 vegetable servings/day* (274; 293) 185 (67.5%) 189 (64.5%) 1.14 (0.81, 1.62) 0.45 1.34 (0.85, 2.11) 0.21 
ESTEEM-Q Score (mean SD) (218; 255) 7.2 (2.0) 5.1 (2.0) 2.1 (1.7, 2.4)^ <0.001 2.0 (1.7, 2.3)^^ <0.001 
Maternal gastrointestinal symptoms       
Fullness of stomach (266; 251) 151 (56.8%) 157 (62.5%) 0.79 (0.55, 1.12) 0.18 0.93 (0.60, 1.43) 0.73 
Bloatedness (267; 250) 76 (28.5%) 92 (36.8%) 0.68 (0.47, 0.99) 0.04 0.61 (0.39, 0.96) 0.03 
Vomiting (266; 250) 35 (13.2%) 44 (17.6%) 0.71 (0.44, 1.15) 0.16 0.61 (0.33, 1.14) 0.12 
Nausea (267; 252) 70 (26.2%) 83 (32.9%) 0.72 (0.50, 1.06) 0.09 0.82 (0.52, 1.31) 0.41 
Indigestion (267; 250) 126 (47.2%) 110 (44.0%) 1.14 (0.80, 1.61) 0.47 1.08 (0.69, 1.69) 0.73 
Constipation (267; 251) 70 (26.2%) 82 (32.7%) 0.73 (0.50, 1.07) 0.11 0.73 (0.46, 1.15) 0.17 
Diarrhoea (265; 250) 32 (12.1%) 39 (15.6%) 0.74 (0.45, 1.23) 0.25 0.60 (0.34, 1.09) 0.09 
Health and physical activity       
Physical activity (MET) (mean SD) (262; 
270) 
6.9 (1.6) 6.7 (2.0)  0.24 (-0.07, 0.56)^ 0.13 0.21 (-0.10, 0.51)^^ 0.19 
Health thermometer (mean SD) (257; 252) 73.1 (16.9) 69.9 (18.6) 3.3 (0.2, 6.4)^ 0.038 3.0 (0.1, 5.9)^^ 0.046 
SD-standard deviation; OR-Odds ratio; CI-Confidence interval; ^mean difference;  ^^adjusted mean difference; MET: Metabolic Equivalent 374 
of Task minutes per week; *score of 1 for each positive response *OR: adjusted for the minimisation factors, age, history of previous 375 
gestational diabetes, family history of hypertensive disorders (hypertension and / or pre-eclampsia), family history of diabetes, history of 376 
stillbirth and the recruitment center. 377 
 378 
 379 
Outcomes 380 
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We did not observe a significant reduction in the odds of the composite maternal (aOR 0∙76, 381 
95% CI 0∙56-1∙03, p=0.08), and composite offspring (aOR 0∙79, 95% CI 0∙58-1∙08, p=0.14) 382 
outcomes with Mediterranean-style diet than usual care. For the individual components of the 383 
maternal composite outcome, there was a significant reduction in the odds of gestational 384 
diabetes by 35% (aOR 0∙65, 95% CI 0∙47-0∙91, p=0.01), but no significant effect on pre-385 
eclampsia (aOR 1∙4, 95% CI 0∙84-2∙4, p=0.19) in the intervention group. We did not observe 386 
a significant reduction in any of the individual component of the composite offspring 387 
outcome (small for gestational age fetus aOR 0∙78, 95% CI 0∙53-1∙15, p=0.21; stillbirth aOR 388 
0∙49, 95% CI 0∙04-5∙57, p=0.56; and admission to the neonatal unit aOR 0∙79, 95% CI 0∙53-389 
1∙18, p=0.25) (Table 3).  390 
 391 
 392 
Table (3): Effects of Mediterranean-style diet in pregnancy on the primary composite 393 
maternal, and composite offspring outcomes, and their individual components  394 
 395 
Outcomes(N intervention; control) Intervention 
(N=553) n 
(%) 
Control(N=5
85)n (%) 
Crude OR(95% 
CI) 
Crude p 
value 
Adjusted 
OR*(95% CI) 
Adjusted 
p value 
Primary outcomes 
Composite maternal outcome (486; 500) 111 (22.8%) 143 (28.6%) 0.74 (0.55, 0.98) 0.04 0.76 (0.56, 1.03) 0.08 
Composite offspring outcome (531; 564) #  92 (17.3%) 118 (20.9%) 0.79 (0.59, 1.07) 0.13 0.79 (0.58, 1.08) 0.14 
Individual components of the composite outcomes 
Gestational diabetes (477; 497) 84 (17.6%) 124 (24.9%) 0.64 (0.47, 0.88) 0.01 0.65 (0.47, 0.91) 0.01 
Pre-eclampsia (552; 585) 34 (6.2%) 27 (4.6%) 1.36 (0.81, 2.28) 0.25 1.43 (0.84, 2.43) 0.19 
Small for gestational age fetus (531; 564)$ # 52 (9.8%) 69 (12.2%) 0.78 (0.53, 1.14) 0.20 0.78 (0.53, 1.15) 0.21 
Stillbirth (533; 566) # 1 (0.2%) 2 (0.4%) 0.53 (0.05, 5.86) 0.60 0.49 (0.04, 5.57) 0.56 
Admission to neonatal unit (533; 565) # 49 (9.2%) 64 (11.3%) 0.79 (0.54, 1.17) 0.25 0.79 (0.53, 1.18) 0.25 
OR: Odds Ratio, MD: mean difference, CI: Confidence Interval *OR: adjusted for the minimisation factors, age, history of previous 396 
gestational diabetes, family history of hypertensive disorders (hypertension and / or pre-eclampsia), family history of diabetes, history of 397 
stillbirth and the recruitment center. $Small for gestation age: <10th centile using customised charts adjusting for maternal height, weight, 398 
parity, gestation at delivery and ethnic origin # Denominator for components of composite offspring outcome excludes women with 399 
miscarriage and termination of pregnancy. *Women with gestational diabetes or with preeclampsia were considered to have the composite 400 
maternal outcome even if the other component of outcome was missing;  for the composite outcome to be considered absent both 401 
components needed to be confirmed absent – otherwise the composite outcome was considered to be missing. Similar approach was used for 402 
the composite offspring outcome. 403 
 404 
 405 
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Women allocated to the intervention gained less weight in pregnancy (MD -1∙2 kg, 95% CI -406 
2∙2 to -0∙2, p=0.03) than the control group. There were no differences between the groups for 407 
other secondary outcomes (Table 4). 408 
 409 
Table (4): Effects of Mediterranean-style diet in pregnancy on the secondary maternal and 410 
offspring outcomes in pregnant women with metabolic risk factors  411 
 412 
OutcomesN (intervention; 
control) 
Intervention   
n (%) 
Controln (%) Crude ORor MD^ 
(95% CI) 
Crude 
p 
value 
Adjusted OR or MD^^ 
(95% CI) 
Adjuste
d p 
value 
Maternal clinical outcomes       
Gestational weight gain (kg) 
(mean, SD) (230; 238) 
6.8 (5.6)  8.3 (6.4)  -1.5 (-2.6, -0.4)^ 0.01 -1.2 (-2.2, -0.2) ^^ 0.03 
Preterm delivery <37 weeks 
(545; 579) 
52 (9.5%)  64 (11.1%)  0.85 (0.58, 1.3) 0.41 0.82 (0.55, 1.22) 0.33 
Preterm delivery <34 weeks 
(545; 579) 
23 (4.2%)  26 (4.5%)  0.94 (0.53, 1.66) 0.82 0.92 (0.51, 1.67) 0.79 
Antepartum haemorrhage 
(548; 580) 
9 (1.6%)  13 (2.2%)  0.73 (0.31, 1.72) 0.47 0.70 (0.29, 1.72) 0.44 
Caesarean section (539; 571) 175 (32.6%) 176 (30.8%) 1.08 (0.84, 1.39) 0.56 1.06 (0.8, 1.37) 0.65 
Anaemia (547; 578) 114 (20.8%)  129 (22.3%)  0.92 (0.69, 1.22) 0.55 0.91 (0.66, 1.23) 0.53 
Admission to HDU or ITU 
(527; 566) 
18 (3.4%)  24 (4.2%)  0.80 (0.43, 1.49) 0.48 0.79 (0.42, 1.50) 0.48 
Offspring outcomes 
Hypoxic ischaemic 
encephalopathy (531; 561) 
2 (0.4%)  4 (0.7%)  0.53 (0.10, 2.89) 0.46 0.56 (0.09, 3.46) 0.53 
Neonatal death (532; 566) 3 (0.6%)  1 (0.2%)  3.20 (0.33, 30.90) 0.31 3.93 (0.33, 46.10) 0.28 
Birth weight (g) (mean, SD) 
(531; 565) 
3340.1 (623.1) 3277.6 (599.4)  62.4 (-10.0, 134.9) ^ 0.09 56.0 (-15.4, 127.4)^^ 0.12 
Very small for gestational age 
(customised) (531; 564)* 
17 (3.2%)  21 (3.7%)  0.86 (0.45, 1.64) 0.64 0.84 (0.43, 1.63) 0.60 
Large for gestational age 
(customised) (531; 564)* 
73 (13.7%)  64 (11.3%)  1.25 (0.87, 1.78) 0.23 1.23 (0.86, 1.78) 0.26 
Small for gestational age 
(population based) (531; 
564)** 
61 (11.5%)  86 (15.2%)  0.72 (0.51, 1.03) 0.07 0.73 (0.51, 1.04) 0.08 
Very small for gestational age 
(population based) (531; 
564)** 
30 (5.6%)  33 (5.9%)  0.96 (0.58, 1.60) 0.89 0.96 (0.57, 1.61) 0.87 
Large for gestational age 
(population based) (531; 
564)** 
59 (11.1%)  61 (10.8%)  1.03 (0.71, 1.51) 0.88 1.01 (0.69, 1.49) 0.94 
Maternal laboratory outcomes (mean, SD) 
Triglycerides (mmol/L) (217; 
257) 
3.0 (1.3)  2.9 (1.3)  0.08 (-0.15, 0.31) ^ 0.50 0.04 (-0.15, 0.22) ^^ 0.70 
HDL (mmol/L) (221; 258) 1.8 (0.5)  1.8 (0.5)  0.03 (-0.06, 0.12)  0.54 0.02 (-0.05, 0.09) ^^ 0.51 
Ratio of triglycerides to 
cholesterol (215; 255) 
0.5 (0.2)  0.5 (0.2)  0.01 (-0.03, 0.04)^ 0.67 0.01 (-0.02, 0.04) ^^ 0.72 
Non-HDL (mmol/L) (219; 
256) 
4.4 (1.3)  4.3 (1.3)  0.03 (-0.21, 0.27)  0.82 0.01 (-0.18, 0.19) ^^ 0.93 
 413 
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SD-standard deviation; OR-Odds ratio; MD: mean difference; CI-Confidence interval; ITU- Intensive Treatment Unit; HDU- High 414 
Dependency Unit; HDL-High Density Lipoprotein; * Customised birth weight centile adjusted for maternal height, weight, parity, 415 
gestational age at delivery and ethnic origin;  ** Population based birth weight centile;  ^mean difference;  ^^adjusted mean difference 416 
***OR: adjusted for the minimisation factors, age, history of previous gestational diabetes, family history of hypertensive disorders 417 
(hypertension and / or pre-eclampsia), family history of diabetes, history of stillbirth and the recruitment center. 418 
 419 
 420 
A sensitivity analysis that imputed missing outcomes under varying departures from the 421 
missing-at-random assumption found the results to be qualitatively unchanged even when the 422 
odds ratio for missing vs. non-missing outcomes was as high as 3 or as low as 1/3 ( S1 Fig).  423 
There were no major differences in the treatment effect for composite maternal or offspring 424 
outcomes within the subgroups of maternal obesity, chronic hypertension or raised 425 
triglycerides (Table 5).  426 
 427 
Table (5):  Subgroup analysis on the effects of Mediterranean-style diet in pregnancy on the 428 
composite maternal and offspring outcomes and their individual components  429 
 430 
Outcomes N (intervention; control) Intervention n (%) Control n (%) Adjusted OR  
(95% CI) 
Adjusted p 
value 
Composite maternal outcome 
Obese (348,352) 81 (23.3%) 104 (29.5%) 0.72 (0.50, 1.02) 0.55 
Not Obese (138,148) 30 (21.7%) 39 (26.4%) 0.88 (0.50, 1.57) 
 
Raised Triglycerides (199,212) 50 (25.1%) 71 (33.5%) 0.68 (0.43, 1.08) 0.59 
Normal triglycerides (243,245) 51 (21.0%) 61 (24.9%) 0.81 (0.52, 1.26) 
 
Chronic hypertension (30,27) 10 (33.3%) 14 (51.9%) 0.60 (0.19, 1.89) 0.67 
No chronic hypertension (448,461) 100 (22.3%) 125 (27.1%) 0.78 (0.57, 1.07) 
 
Composite offspring outcome 
Obese (373,392) 61 (16.4%) 86 (21.9%) 0.69 (0.48, 1.01) 0.20 
Not obese (158,172) 31 (19.6%) 32 (18.6%) 1.08 (0.61, 1.89) 
 
Raised triglycerides (223,242) 38 (17.0%) 45 (18.6%) 0.94 (0.58, 1.52) 0.37 
Normal triglycerides (258,270) 46 (17.8%) 63 (23.3%) 0.69 (0.45, 1.07) 
 
Chronic hypertension (35,28) 16 (45.7%) 6 (21.4%) 3.08 (0.97, 9.77) 0.02 
No chronic hypertension (487,523) 76 (15.6%) 108 (20.7%) 0.72 (0.52, 1.00) 
 
Pre-eclampsia 
Obese (386,409) 26 (6.7%) 18 (4.4%) 1.65 (0.88, 3.11) 0.40 
Not obese (166,176) 8 (4.8%) 9 (5.1%) 0.99 (0.37, 2.69)  
Raised triglycerides (230,252) 11 (4.8%) 11 (4.4%) 1.13 (0.47, 2.71) 0.91 
Normal triglycerides (270,280) 18 (6.7%) 16 (5.7%) 1.21 (0.59, 2.46)  
Chronic hypertension (36,30) 7 (19.4%) 2 (6.7%) 3.62 (0.65, 20.01) 0.25 
No chronic hypertension (507,542) 27 (5.3%) 24 (4.4%) 1.26 (0.71, 2.24)  
Gestational Diabetes 
Obese (341,349) 61 (17.9%) 92 (26.4%) 0.58 (0.40, 0.86) 0.27 
Not obese (136,148) 23 (16.9%) 32 (21.6%) 0.88 (0.47, 1.65)  
Raised triglycerides (195,212) 41 (21.0%) 63 (29.7%) 0.64 (0.39, 1.04) 0.86 
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Normal triglycerides (238,242) 36 (15.1%) 50 (20.7%) 0.68 (0.41, 1.11)  
Chronic hypertension (27,27) 5 (18.5%) 13 (48.1%) 0.28 (0.07, 1.07) 0.19 
No chronic hypertension (442,458) 78 (17.6%) 107 (23.4%) 0.70 (0.50, 1.00)  
Small for Gestational Age 
Obese (375,397) 33 (8.8%) 51 (12.8%) 0.65 (0.41, 1.03) 0.28 
Not obese (160,174) 19 (11.9%) 21 (12.1%) 1.02 (0.52, 2.00)  
Raised triglycerides (218,239) 20 (9.2%) 23 (9.6%) 1.00 (0.53, 1.91) 0.22 
Normal triglycerides (256,271) 27 (10.5%) 42 (15.5%) 0.60 (0.35, 1.02)  
Chronic hypertension (35,29) 10 (28.6%) 5 (17.2%) 2.02 (0.58, 7.02) 0.09 
No chronic hypertension (491,529) 42 (8.6%) 66 (12.5%) 0.66 (0.43, 0.99)  
Admission to Neonatal unit 
Obese (386,409) 36 (9.3%) 45 (11.0%) 0.86 (0.53, 1.38) 0.60 
Not obese (166,175) 13 (7.8%) 19 (10.9%) 0.67 (0.31, 1.45)  
Raised triglycerides (230,251) 20 (8.7%) 29 (11.6%) 0.74 (0.40, 1.37) 0.73 
Normal triglycerides (270,280) 26 (9.6%) 32 (11.4%) 0.86 (0.49, 1.52)  
Chronic hypertension (36,30) 6 (16.7%) 2 (6.7%) 2.43 (0.43, 13.79) 0.22 
No chronic hypertension (507,541) 43 (8.5%) 59 (10.9%) 0.78 (0.51, 1.20)  
OR: Odds Ratio, CI: Confidence Interval, *OR: adjusted for the minimisation factors, age, history of previous gestational diabetes, family 431 
history of hypertensive disorders (hypertension and / or pre-eclampsia), family history of diabetes, history of stillbirth and the recruitment 432 
center.$Small for gestation age: <10th centile using customised charts adjusting for maternal height, weight, parity, gestation at delivery and 433 
ethnic origin # Denominator for components of composite offspring outcome excludes women with miscarriage and termination of 434 
pregnancy 435 
 436 
Participants in the intervention group reported better overall quality of life with higher Health 437 
Thermometer scores (MD 3∙0, 95% CI 0∙1-5∙9, p=0.046) than those in the control group 438 
(Table 2). Intake of a Mediterranean-style diet apparently reduced bloatedness (aOR 0∙61, 439 
95% CI 0∙39-0∙96, p=0∙03) in pregnancy, but did not affect other symptoms such as nausea, 440 
vomiting or indigestion (Table 2). One woman in the intervention arm had an allergic 441 
reaction to walnuts which resolved spontaneously. There were no serious adverse events in 442 
any of the participants.  443 
 444 
Assessment of dietary intake of the participants using the FFQ showed good to acceptable 445 
agreement with the 24-hour dietary recall method for meat (ICC 0∙56) and fish (ICC 0∙52); 446 
and acceptable agreement for bread (ICC 0∙46), vegetables (ICC 0∙20), legumes (ICC 0∙25), 447 
eggs (ICC 0∙23) and pastries, cakes and sweets (ICC 0∙21). There was good quartile cross-448 
classification agreement for the majority of food groups, except for eggs, legumes, olive oil 449 
and nuts. ESTEEM Q demonstrated moderate to good agreement with the FFQ for the use of 450 
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olive oil (κ 0∙52), fruits (κ 0∙36), butter or margarine (κ 0∙33), sugary drinks (κ 0∙50), fish (κ 451 
0∙30), commercial sweets (κ 0∙35) and nuts (κ 0∙36).  452 
 453 
Meta-analysis of randomised trials on Mediterranean diet in pregnancy 454 
Our literature search identified one randomised trial involving 874 unselected pregnant 455 
women from Spain (St Carlos study). [34] The women were mainly of Caucasian origin and 456 
three-quarters (659/874, 75%) had normal BMI. The intervention was a Mediterranean diet 457 
supplemented with nuts and extra virgin olive oil. The pooled effect estimate (2 trials, 2012 458 
women) showed a consistent reduction in gestational diabetes (OR 0.67, 95% CI 0.53-0.84; I² 459 
= 0%). The intervention did not reduce the rates of other individual components of the 460 
primary composite outcomes such as pre-eclampsia, small-for-gestational age fetus, or 461 
admission to the neonatal care unit. Fig 2 illustrates the forest plots for all conducted meta-462 
analyses.  463 
 464 
Fig 2: Meta-analysis of randomised trials on Mediterranean-style diet in pregnancy 465 
 466 
Discussion 467 
Main findings 468 
In the ESTEEM trial, we successfully implemented a Mediterranean-style diet in a multi-469 
ethnic pregnant population of high-risk women. Mothers who followed the intervention 470 
significantly increased their consumption of nuts, olive oil, fish, white meat, and pulses, and 471 
lowered their intake of red meat, and butter or margarine, compared to the usual care group. 472 
Overall, the intervention did not significantly reduce the composite maternal and offspring 473 
outcomes, still, it had an apparent protective effect to reduce the incidence of gestational 474 
diabetes and the gestational weight gain.   475 
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 476 
Strengths and weaknesses of the study 477 
We registered and published the trial protocol prospectively. [17] Two-thirds of participants 478 
were from ethnic minority groups, who in addition to being at risk of complications, are also 479 
usually difficult to engage in lifestyle interventions. [35] We used a simple, culturally 480 
sensitive, and easy to follow intervention, involved the partners and the wider family, and 481 
provided extra virgin olive oil and nuts. Three-quarters of participants (74%, 410/553) 482 
attended at least one of the planned intervention sessions, a rate that is comparable to other 483 
trials on diet-based interventions in pregnancy. [30,36] Mothers had the flexibility to receive 484 
olive oil and nuts even when they did not attend the face-to-face sessions. We evaluated the 485 
validity of the dietary assessment tools used within our study population for the key food 486 
groups in the Mediterranean diet. In women randomised to the intervention, we observed an 487 
increased intake of not only nuts and olive oil, but also changes in the consumption of other 488 
key components of Mediterranean-style diet such as increased intake of fish, preferential 489 
intake of chicken and turkey over veal and sausages, and reduced consumption of red meat 490 
and butter than the control group, indicating adherence to the overall diet. Our choice of the 491 
individual components of the primary composite outcomes was based on a Delphi survey of 492 
experts who specified the outcomes to be critically important in the evaluation of lifestyle 493 
interventions in pregnancy. [26] The decision to add components to the original primary 494 
outcome was made by a committee independent to the trial team, without access to any data 495 
that may provide insight into the treatment effect.  496 
 497 
We did not find a significant reduction in maternal composite outcome. Majority of our 498 
participants were multigravida (875/1205, 73%). This may explain the relatively low 499 
incidence of pre-eclampsia (61/1138, 5.3%), a condition more commonly observed in the first 500 
pregnancy. Our participants were from diverse ethnic and cultural backgrounds, and we were 501 
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not able to take into account the variations in baseline dietary pattern. However, we ensured 502 
that the diet in the intervention arm was culturally appropriate and adapted to their 503 
individualised need. We did not blind participants or researchers, which is difficult to achieve 504 
in complex dietary interventions, [37] and cannot rule out a Hawthorne effect with women in 505 
the control group accessing the intervention. [38] Despite the overall high follow-up rate, we 506 
could not ascertain the outcome of gestational diabetes in 15% of participants. But this was 507 
below our expected attrition rate of 20%. We did not use additional measures such as 508 
biomarkers to objectively assess the intake of olive oil and nuts. We only obtained 509 
information on dietary intake in about 40% of participants in both groups, a proportion that is 510 
consistent with what was observed in similar dietary trials involving pregnant women. [39] 511 
Although variations in the clinical management of gestational diabetes and pre-eclampsia 512 
might have influenced the offspring outcomes, we consider this less likely as both groups 513 
were managed according to the UK national guidelines. [23,28] In our pre-planned, primary 514 
analysis we adopted a relatively simplistic approach to dealing with missing components of 515 
composite outcomes, which could have potentially introduced bias. We considered post hoc a 516 
more exclusive definition of each composite outcome which required all the respective 517 
components to be non-missing, but the results were similar (for maternal composite outcome 518 
aOR 0.71, 95% CI 0.52-0.97; composite offspring outcome aOR 0.80, 95% CI 0.59-1.09). 519 
Our sensitivity analysis also suggested that our findings were robust to departures from a 520 
‘missing at random’ assumption. 521 
 522 
The primary end point changed after the start of the randomised trial. We consider the 523 
potential risk of bias to be minimal for the following reasons: the decision to change the 524 
endpoint by the independent TSC was based on the emerging evidence base on the burden of 525 
GDM and pre-eclampsia in women with metabolic risk factors, particularly in those from 526 
ethnic minority backgrounds with previous history of GDM; the TSC took into account 527 
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observational evidence on Mediterranean diet in pregnancy and potential reductions in 528 
gestational diabetes; [40,41] the decision was made prior to completion of data collection, 529 
statistical analysis plan development, and without knowledge of outcome data by allocated 530 
groups or any effect estimates; the changes in the endpoints were clearly documented in the 531 
revised protocol, in this paper and were approved by the ethics committee;  we reported the 532 
effects of the intervention on both the composite outcomes, and its individual components, 533 
which includes the original endpoint. We advise caution on the interpretation of the results in 534 
view of the revised endpoints, and this needs to be confirmed in future large trials. 535 
 536 
Comparison with other studies  537 
In our individual participant data (IPD) meta-analysis (36 randomised trials, 12,526 women) 538 
on diet and physical activity in pregnancy, interventions reduced gestational weight gain and 539 
caesarean section rates, but not other maternal or offspring outcomes. [11] For key outcomes 540 
such as gestational diabetes and pre-eclampsia, both aggregate and IPD meta-analyses were 541 
limited by the variations in the definitions between studies. Individual studies had either 542 
shown no benefit, or had insufficient power to detect meaningful differences. [11,30]  543 
 544 
Unlike the effects of Mediterranean diet in general population, [42] we did not observe any 545 
differences in the lipid levels between both arms in our study. We found a moderate reduction 546 
in the mean gestational weight gain with intervention than control, consistent with reports on 547 
protective role of Mediterranean diet against obesity and weight gain. [43] This could be 548 
attributed to the satiety achieved with a plant-based diet, increased fibre intake, and the low 549 
glycaemic index of promoted food groups such as the pulses. [43]  But lowered weight gain 550 
did not translate into reductions in composite maternal and offspring composite outcomes. In 551 
the St Carlos trial, the beneficial effect of Mediterranean diet was observed for gestational 552 
diabetes but not for gestational weight gain. It is possible that this beneficial effect on 553 
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gestational diabetes was mediated through the high intake of dietary polyphenols found in 554 
key components of the Mediterranean diet such as extra virgin olive oil and nuts, by reducing 555 
insulin resistance, stimulating insulin secretion, activating insulin receptors, modulating 556 
glucose release, and increasing the uptake of glucose in the insulin-sensitive tissues. [44] 557 
Although Mediterranean diet has been shown to reduce high blood pressure in the general 558 
population at risk [45], and high adherence to this diet reduced fetal growth restriction in 559 
observational studies [7], we did not observe any reductions in the risk of pre-eclampsia or 560 
any offspring outcome. This could be attributed to the fact that since placental remodelling 561 
occurs in early pregnancy, the dietary intervention might not have been started early enough 562 
or long enough to observe any benefit. [46] Furthermore, we observed fewer women with 563 
pre-eclampsia than expected in this high risk group. Despite the increase in the sample size in 564 
the meta-analysis, there was no reduction in the risk of pre-eclampsia.’ 565 
 566 
Relevance to clinical practice and research  567 
The results of ESTEEM combined with previous evidence show that supplementation of 30g 568 
of mixed nuts per day and extra virgin olive oil can lower gestational weight gain, and has 569 
strong potential to minimise risk of gestational diabetes. Delivering such dietary intervention 570 
is feasible as part of routine antenatal care, reflecting the pragmatic approach adopted in our 571 
trial.  A definitive large-scale trial on Mediterranean-style diet will need to assess both 572 
reduction in gestational diabetes and whether it translates to the prevention of type 2 diabetes 573 
in the mother in later life. The cost-effectiveness of following a Mediterranean-style diet also 574 
needs to be formally studied with a full economic evaluation. Although we did not find any 575 
differences between the groups in short-term offspring outcomes, we do not know the 576 
potential impact of the in utero exposure to the various dietary components of the 577 
intervention on long term outcomes such as childhood obesity, and other conditions such as 578 
asthma and allergy disorders in the offspring. Furthermore, the long-term  reduction in 579 
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gestational diabetes in the mother on child outcomes also needs further evaluation.  Future 580 
studies should assess the effect of in utero exposure to Mediterranean-style diet on children, 581 
particularly to nuts and olive oil, on childhood obesity, allergy, and asthma. [47]  582 
 583 
Conclusion 584 
A simple, individualised, Mediterranean-style diet in pregnancy did not reduce the overall 585 
risk of adverse maternal and offspring complications, but has the potential to reduce 586 
gestational weight gain and the risk of gestational diabetes.  587 
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